First Trimester Abortion Guidelines and Protocols Surgical and Medical Procedures from Choice, a World of Possibilities
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hysteroscopy with Dilation and Curretage (D & C)
501 19th Street, Trustees Tower FORT SANDERS WOMEN’S SPECIALISTS 1924 Pinnacle Point Way Suite 401, Knoxville Tn 37916 P# 865-331-1122 F# 865-331-1976 Suite 200, Knoxville Tn 37922 Dr. Curtis Elam, M.D., FACOG, AIMIS, Dr. David Owen, M.D., FACOG, Dr. Brooke Foulk, M.D., FACOG Dr. Dean Turner M.D., FACOG, ASCCP, Dr. F. Robert McKeown III, M.D., FACOG, AIMIS, Dr. Steven Pierce M.D., Dr. G. Walton Smith, M.D., FACOG, Dr. Susan Robertson, M.D., FACOG HYSTEROSCOPY WITH DILATION AND CURRETAGE (D & C) Please read and sign the following consent form when you feel that you completely understand the surgical procedure that is to be performed and after you have asked all of your questions. If you have any further questions or concerns, please contact our office prior to your procedure so that we may clarify any pertinent issues. Definition: HysterosCopy is an outpatient procedure that allows your doctor direct visualization of the inside of the uterine cavity (womb) by inserting a thin lighted telescope (hysteroscope) through the vagina (birth canal) and cervix, without making an abdominal incision. This procedure enables your doctor to examine the lining of the uterus, look for polyps, fibroids, scar tissue, blockages of the fallopian tubes, and abnormal partitions. In addition, this procedure allows your doctor to remove or surgically treat many of the abnormalities seen. Dilation and Curettage (D&C) allows your doctor to take a sample of the tissue that lines your uterus (endometrium) and/or to remove polyps, fibroid tumors, or hyperplasia. Suction D&C is used in cases of miscarriage. -
Do Nothing, Do Something, Aspirate: Management of Early Pregnancy
Disclosure Do Nothing, Do Something, • I train providers in Nexplanon insertion and removal Aspirate: • I do not receive any honoraria for this Management Of Early Pregnancy Loss Sarah Prager, MD, MAS Department of Obstetrics and Gynecology University of Washington Objectives Nomenclature By the end of this workshop participants will be able to: Early Pregnancy Loss/Failure (EPL/EPF) Spontaneous Abortion (SAb) 1. Understand diagnosis of early pregnancy loss (EPL) Miscarriage 2. Describe EPL management options in a clinic or the ED. 3. Describe the uterine evacuation procedure using These are all used interchangeably! the manual uterine aspirator (MUA). 4. Demonstrate the use of MUA for uterine Manual Uterine Aspiration/Aspirator (MUA) evacuation using papayas as simulation models. Manual Vacuum Aspiration/Aspirator (MVA) 5. Express an awareness of their own values related Uterine Evacuation to pregnancy and EPL management. Suction D&C/D&C/dilation and curettage Background Imperfect obstetrics: most don’t continue • Early Pregnancy Loss (EPL) is the most common complication of early pregnancy • 8–20% clinically recognized pregnancies • 13–26% all pregnancies • ~ 800,000 EPLs each year in the US • 80% of EPLs occur in 1st trimester • Many women with EPL first contact medical care through the emergency room Brown S, Miscarriage and its associations. Sem Repro Med. 1 Samantha Risk Factors for EPL • Age • 26 yo G2P1 presents to the • Prior SAb emergency room with vaginal • Smoking bleeding after a positive • Alcohol home pregnancy test. An • Caffeine (controversial) ultrasound shows a CRL of • Maternal BMI <18.5 or >25 7mm but no cardiac activity. • Celiac disease (untreated) • She wants to know why this • Cocaine happened. -
Dilation and Curettage (D&C) Consent Form
Dilation and Curettage (D&C) Consent Form Patient Name: ____________________________________________ Date of Birth: __________ Guardian Name (if applicable): ________________________________ Patient ID: ___________ Washington State law guarantees that you have both the right and the obligation to make decisions regarding your health care. Your physician can provide you with the necessary information and advice, but as a member of the health care team, you must participate in the decision making process. This form acknowledges your consent to treatment recommended by your physician. 1 MY PROCEDURE I hereby give my consent for Dr. or/and his/her associates to perform a Dilation and Curettage upon me. I understand the procedure is to be performed at the First Hill Surgery Center. This has been recommended to me by my physician in order to diagnose or treat dysfunctional uterine bleeding, menorrhagia (heavy menstrual bleeding) increased endometrial thickness, uterine polyps, and/or miscarriage. I understand that the procedure or treatment can be described as follows: The cervix is mechanically dilated and the lining of the uterus is either scraped or suctioned to remove tissue for possible biopsy. This procedure is routinely done in an outpatient surgery center and typically takes 15-20 minutes to complete. General anesthesia or sedation may be required for this procedure and will be administered by a qualified anesthesiologist. Your anesthesiologist will be available to discuss this further with you on the day of your procedure. 2 MY BENEFITS Some potential benefits of this procedure include: Removing tissue from the uterus may temporarily relieve abnormal bleeding lining; removing tissue for biopsy of the uterine lining; resolution of failed pregnancy. -
Model for Teaching Cervical Dilation and Uterine Curettage
Model for Teaching Cervical Dilation and Uterine Curettage Linda J. Gromko, MD, and Sam C. Eggertsen, MD Seattle, W a s h in g to n t least 15 percent of clinically recognizable pregnan METHODS A cies terminate in fetal loss, with the majority occur ring in the first trimester.1 Cervical dilation and uterine The fabric model was developed under the guidance of curettage (D&C) is frequently important in the manage physicians at the University of Washington Department ment of early pregnancy loss to control bleeding and re of Family Medicine and is commercially available.* The duce the risk of infection. D&Cs are also done for thera model, designed to approximate a 10-week last-menstrual- peutic first trimester abortions in family practice settings. period-sized uterus, is supported by elastic “ligaments” Resident experience may vary greatly, and some may feel on a wooden frame (Figure 1). A standard Graves spec inadequately trained in this procedure. The initial use of ulum can be inserted into the “vagina,” permitting vi gynecologic instruments (ie, tenaculum, sound, dilators, sualization of a cloth cervix. After placement of a tena curette) can feel awkward to the learner, and extensive culum onto the cervix, a paracervical block can be verbal tutoring may be discomfiting to the awake patient. demonstrated and the uterus sounded. Progressive dilation Training on a model can reduce these problems. After with Pratt or Denniston dilators follows: a drawstring al gaining basic skills on a model, the resident can focus on lows for the cervix to retain each successive degree of di gaining additional skills and refining technique during pa lation. -
University of Birmingham Uterotonic Agents for Preventing Postpartum
University of Birmingham Uterotonic agents for preventing postpartum haemorrhage Gallos, Ioannis D; Williams, Helen M; Price, Malcolm J; Merriel, Abi; Gee, Harold; Lissauer, David; Moorthy, Vidhya; Tobias, Aurelio; Deeks, Jonathan J; Widmer, Mariana; Tunçalp, Özge; Gülmezoglu, Ahmet Metin; Hofmeyr, G Justus; Coomarasamy, Arri DOI: 10.1002/14651858.CD011689.pub2 License: None: All rights reserved Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Gallos, ID, Williams, HM, Price, MJ, Merriel, A, Gee, H, Lissauer, D, Moorthy, V, Tobias, A, Deeks, JJ, Widmer, M, Tunçalp, Ö, Gülmezoglu, AM, Hofmeyr, GJ & Coomarasamy, A 2018, 'Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis', Cochrane Database of Systematic Reviews, vol. 2018, no. 4, CD011689. https://doi.org/10.1002/14651858.CD011689.pub2 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility:17/05/2018 Gallos ID, Williams HM, Price MJ, Merriel A, Gee H, Lissauer D, Moorthy V, Tobias A, Deeks JJ, Widmer M, Tunçalp Ö, Gülmezoglu AM, Hofmeyr GJ, Coomarasamy A. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub2. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. -
Medical Abortion Reference Guide INDUCED ABORTION and POSTABORTION CARE at OR AFTER 13 WEEKS GESTATION (‘SECOND TRIMESTER’) © 2017, 2018 Ipas
Medical Abortion Reference Guide INDUCED ABORTION AND POSTABORTION CARE AT OR AFTER 13 WEEKS GESTATION (‘SECOND TRIMESTER’) © 2017, 2018 Ipas ISBN: 1-933095-97-0 Citation: Edelman, A. & Mark, A. (2018). Medical Abortion Reference Guide: Induced abortion and postabortion care at or after 13 weeks gestation (‘second trimester’). Chapel Hill, NC: Ipas. Ipas works globally so that women and girls have improved sexual and reproductive health and rights through enhanced access to and use of safe abortion and contraceptive care. We believe in a world where every woman and girl has the right and ability to determine her own sexuality and reproductive health. Ipas is a registered 501(c)(3) nonprofit organization. All contributions to Ipas are tax deductible to the full extent allowed by law. For more information or to donate to Ipas: Ipas P.O. Box 9990 Chapel Hill, NC 27515 USA 1-919-967-7052 [email protected] www.ipas.org Cover photo: © Ipas The photographs used in this publication are for illustrative purposes only; they do not imply any particular attitudes, behaviors, or actions on the part of any person who appears in the photographs. Printed on recycled paper. Medical Abortion Reference Guide INDUCED ABORTION AND POSTABORTION CARE AT OR AFTER 13 WEEKS GESTATION (‘SECOND TRIMESTER’) Alison Edelman Senior Clinical Consultant, Ipas Professor, OB/GYN Oregon Health & Science University Alice Mark Associate Medical Director National Abortion Federation About Ipas Ipas works globally so that women and girls have improved sexual and reproductive health and rights through enhanced access to and use of safe abortion and contraceptive care. -
Parental Consent Form for a Minor Seeking Abortion
Parental Consent Form for a Minor Seeking Abortion Parental Statement: I certify that I, ___________________________, am the parent of _________________________________ (name of parent) (minor daughter name) and give consent for ____________________________ to perform an abortion on my daughter. I understand (physician name) that any person who knowingly makes a fraudulent statement in this regard commits a felony. Date: , 20 . Signature of Parent/Managing Conservator/Guardian I certify I have witnessed the execution of this consent by the parent. Subscribed and sworn to before me on this day of 20 (day) (month) Seal NOTARY PUBLIC in and for The State of OKLAHOMA My commission expires: Required attachments: - Copy of government-issued proof of identification - Written documentation that establishes that he or she is the lawful parent of the pregnant female Physician Statement: I, ____________________________, certify that according to my best information and belief, a reasonable person under (Physician name) similar circumstances would rely on the information presented by both the minor and her parent as sufficient evidence of identity. Date: , 20 . Signature of Physician ___________ (Parent Initials) Oklahoma State Department of Health 11/2013 Health Care Information Page 1 of 9 Consent of a Minor & Parental Consent Statement The law of the State of Oklahoma (Title 63, Section 1-740.13) requires physicians to obtain the consent of the minor and parent using this form prior to performing an abortion on a minor who is not emancipated. -
Dilation and Curettage (D&C)
Fact Sheet From ReproductiveFacts.org The Patient Education Website of the American Society for Reproductive Medicine Dilation and Curettage (D&C) This fact sheet was developed in collaboration with The Society of Reproductive Surgeons “Dilation and curettage” (D&C) is a short surgical as intestines, bladder, or blood vessels, are injured. If procedure that removes tissue from your uterus (womb). any of these organs are injured, they must be repaired You may need this procedure if you have unexplained with surgery. However, if no other organs have been or abnormal bleeding, or if you have delivered a baby injured, long-term complications from a perforation are and placental tissue remains in your womb. D&C also is extremely rare and the uterus heals on its own. performed to remove pregnancy tissue remaining from can occur after a D&C. If you are not a miscarriage or an abortion. Infections pregnant at the time of your D&C, this complication How is the procedure done? is extremely rare. However, 10% of women who were D&C can be done in a doctor’s office or in the hospital. pregnant before their D&C can get an infection, usually You may be given medications to relax you or to put you within 1 week of the procedure. It may be related to a to sleep for a short time. Your doctor will slowly widen sexually transmitted infection or due to normal bacteria the opening to your uterus (cervix). Opening your cervix that pass from the vagina into the uterus during or can cause cramping. -
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems. -
Abortion by Rape Victim: a Dilemma in the Drat of Penal Code and Indonesian Health Law
Journal of Law and Legal Reform JOURNAL (2020 OF), 1 (LAW4), pp. & 631 LEGAL-640. REFORM VOLUME 1(4) 2020 631 DOI: https://doi.org/10.15294/jllr.v1i4.39659 ISSN (Print) 2715-0941, ISSN (Online) 2715-0968 RESEARCH ARTICLE ABORTION BY RAPE VICTIM: A DILEMMA IN THE DRAT OF PENAL CODE AND INDONESIAN HEALTH LAW Fikri Ariyad1, Ali Masyhar2 1 LBH Rumah Pejuang Keadilan Kota Semarang, Indonesia 2 Faculty of Law, Universitas Negeri Semarang, Indonesia [email protected] CITED AS Ariyad, F., & Masyhar, A. (2020). Abortion by Rape Victim: A Dilemma in the Drat of Penal Code and Indonesian Health Law. Journal of Law and Legal Reform, 1(4), 631-640. https://doi.org/10.15294/jllr.v1i4.39659 ABSTRACT In this present time, the debate about abortion in Indonesia is increasingly crowded. Abortion is also carried out by women - victims of rape to reduce the burden they suffered. The regulation on abortion in Indonesia has been regulated in the statutory regulations, namely the Criminal Code, especially in Article 346, Article 347, Article 348, and Article 349. In the RKUHP (Draft of Criminal Code), abortion regulation is regulated in two chapters namely, Chapter XIV Article 501 and Chapter XIX Articles 589, 590, 591, 592. In addition, the government has also issued several regulations governing abortion such as Government Regulation No. 61 of 2014 concerning Reproductive Health and also Law No. 36 of 2009 concerning health. However, the various regulations that exist between the Criminal Code, RKUHP, PP and the Act actually contradict to each other. There is no synchronization between the regulations regarding abortion by women rape victims. -
Abortion Policy Landscape-India2
First Second Post-Abortion Trimester Trimester Care Specialists (ob gyns) WHO Non-specialists (general physicians) Medical abortion ** *** (using mifepristone (Up to 9 weeks) & misoprostol combination) Surgical abortion HOW (vacuum aspiration) Surgical abortion (dilatation & evacuation) All public-sector Secondary and tertiary public- Where facilities and All public and approved private sector facilities private sector facilities/ and approved facilities clinics**** private facilities *Qualiication and training criteria apply. **The Drug Controller General of India limits the use of MA drugs upto nine weeks. However, the national CAC guidelines10 include drug protocol for second trimester abortions in accordance with WHO Guidelines 2014, for reference. *** Misoprostol only. **** MA upto seven weeks can also be prescribed from an outpatient clinic with an established referral access to MTP-approved facility. REFERENCES 1 United Nations, Department of Economic and Social Aairs, Population Division (2019). World Population Prospects 2019, Online Edition. Rev. 1 https://population.un.org/wpp/Download/Standard/Population/ 2 Census of India 2011 http://www.censusindia.gov.in/2011census/population_enumeration.html 3 Sample Registration System 201416 http://www.censusindia.gov.in/vital_statistics/ SRS_Bulletins/MMR%20Bulletin-201416.pdf 4 National Family Health Survey 4 (201516) http://rchiips.org/nhs/pdf/NFHS4/India.pdf 5 Maternal Mortality Ratio: India, EAG & Assam, Southern States and Other States https://www.niti.gov.in/content/maternal-mortality-ratio-mmr-100000-live-births ABORTION 6 National Family Health Survey 1 (199293) http://rchiips.org/nhs/india1.shtml 7 Sample Registration Survey. Maternal Mortality in India: 19972003. Trends, Causes and Risk Factors. Registrar General. India http://www.cghr.org/wordpress/wp-content/uploads/RGICGHRMaternal-Mortality-in- India-1997%E2%80%932003.pdf POLICY LANDSCAPE 8 Banerjee et al. -
Malaysian Statistics on Medicines 2009 & 2010
MALAYSIAN STATISTICS ON MEDICINES 2009 & 2010 Edited by: Siti Fauziah A., Kamarudin A., Nik Nor Aklima N.O. With contributions from: Faridah Aryani MY., Fatimah AR., Sivasampu S., Rosliza L., Rosaida M.S., Kiew K.K., Tee H.P., Ooi B.P., Ooi E.T., Ghan S.L., Sugendiren S., Ang S.Y., Muhammad Radzi A.H. , Masni M., Muhammad Yazid J., Nurkhodrulnada M.L., Letchumanan G.R.R., Fuziah M.Z., Yong S.L., Mohamed Noor R., Daphne G., Chang K.M., Tan S.M., Sinari S., Lim Y.S., Tan H.J., Goh A.S., Wong S.P., Fong AYY., Zoriah A, Omar I., Amin AN., Lim CTY, Feisul Idzwan M., Azahari R., Khoo E.M., Bavanandan S., Sani Y., Wan Azman W.A., Yusoff M.R., Kasim S., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Suganthi T., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I, Wan Hamilton W.H., Zaridah S., Maisarah A.H., Rohan Malek J., Selvalingam S., Lei C.M., Hazimah H., Zanariah H., Hong Y.H.J., Chan Y.Y., Lin S.N., Sim L.H., Leong K.N., Norhayati N.H.S, Sameerah S.A.R, Rahela A.K., Yuzlina M.Y., Hafizah ZA ., Myat SK., Wan Nazuha W.R, Lim YS,Wong H.S., Rosnawati Y., Ong S.G., Mohd. Shahrir M.S., Hussein H., Mary S.C., Marzida M., Choo Y. M., Nadia A.R., Sapiah S., Mohd. Sufian A., Tan R.Y.L., Norsima Nazifah S., Nurul Faezah M.Y., Raymond A.A., Md.